A cohort of these so-called xenopatients showed amplification of HER2, particularly in RAS wild-type tumours, suggesting enrichment in this cohort, which showed high and sustained sensitivity to combination EGFR and HER2 inhibition. This evidence concerns the gene ERBB2 and neoplasm.